Scarica l'app Stockscreener
25.32
9.37%
2.17
Uniqure N V Borsa (QURE) Ultime notizie
uniQure N.V. Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - FinancialContent
uniQure schedules FDA meeting to discuss accelerated approval for HD therapy - Investing.com Nigeria
uniQure (QURE) Surges on FDA Meeting for Gene Therapy Approval - GuruFocus
UniQure Announces FDA Type A Meeting To Discuss BLA Data For Huntington's Gene Therapy - Nasdaq
US-listed shares of uniQure rise 13% premarket as FDA review talks revive hopes for Huntington's therapy - MarketScreener
uniQure's (QURE) Gene Therapy for Huntington's Disease Advances with FDA Meeting - GuruFocus
uniQure gains as FDA sets up meeting on gene therapy (QURE:NASDAQ) - Seeking Alpha
uniQure prepares for FDA Type A meeting on AMT-130 - TipRanks
uniQure stock soars after FDA meeting scheduled on Huntington’s therapy By Investing.com - Investing.com UK
uniQure stock soars after FDA meeting scheduled on Huntington’s therapy - Investing.com
uniQure Announces Type A Meeting Scheduled with FDA - The Manila Times
uniQure N.V. Schedules FDA Meeting for AMT-130 Approval - TradingView — Track All Markets
FDA to review data on experimental Huntington's gene therapy at uniQure - Stock Titan
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
Is uniQure N.V. stock supported by strong fundamentals2025 Risk Factors & Verified Momentum Stock Alerts - ulpravda.ru
uniQure: Now What? (NASDAQ:QURE) - Seeking Alpha
How sustainable is uniQure N.V. stock dividend payout2025 Growth vs Value & Weekly Market Pulse Alerts - ulpravda.ru
Pullback Watch: Is uniQure N.V. stock attractive for long term wealth building2025 Market Outlook & Weekly Hot Stock Watchlists - ulpravda.ru
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
How (QURE) Movements Inform Risk Allocation Models - Stock Traders Daily
QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP - Business Wire
Wells Fargo Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $60 - 富途牛牛
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure NV (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - FinancialContent
uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen - MarketBeat
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure N.V. (QURE) Stock Analysis: Unveiling a 131% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
How reliable is uniQure NV UQ1 stock dividend growth2025 Big Picture & Technical Pattern Based Buy Signals - moha.gov.vn
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, - GlobeNewswire
QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP En - GuruFocus
QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - PR Newswire
QURE INVESTIGATION REMINDER: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
Whittier Daily News - FinancialContent
Understanding Momentum Shifts in (QURE) - Stock Traders Daily
uniQure N.V. (NASDAQ:QURE) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
uniQure (NASDAQ:QURE) Trading 5.4% HigherWhat's Next? - MarketBeat
Gene therapy genie back in the bottle? - BioWorld MedTech
uniQure Notice of Investigation: Kessler Topaz Meltzer & - GlobeNewswire
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourage - GuruFocus
uniQure (NASDAQ:QURE) Trading Down 4.6%Here's Why - MarketBeat
Cell And Gene Therapy Leaders See Transformative Results Outweighing Industry Setbacks - Citeline News & Insights
What do analysts think about UniQure (QURE)? - MSN
What Do Analysts Think About UniQure (QURE)? - Finviz
How uniQure N.V. stock benefits from tech adoptionJuly 2025 Closing Moves & Fast Moving Stock Watchlists - Улправда
Quarterly Earnings: How uniQure N.V. stock benefits from tech adoptionJuly 2025 Setups & Reliable Breakout Forecasts - Улправда
Is uniQure N.V. stock positioned for long term growthLong Setup & Growth-Oriented Investment Plans - ulpravda.ru
What hedge fund moves indicate for uniQure N.V. (UQ1) stockJuly 2025 Breakouts & AI Powered Buy/Sell Recommendations - Улправда
Revisiting UniQure (NASDAQ:QURE) - Seeking Alpha
uniQure: Why Waiting For Clarity Beats Chasing The Next Step Jump (NASDAQ:QURE) - Seeking Alpha
uniQure (NASDAQ:QURE) Shares Up 14%What's Next? - MarketBeat
Sanders Morris Harris LLC Makes New $5.08 Million Investment in uniQure N.V. $QURE - MarketBeat
Revenue per share of uniQure N.V. – LSX:A1XDTV - TradingView — Track All Markets
What's Going On With uniQure Stock On Tuesday? - Benzinga
uniQure (NASDAQ:QURE) Shares Gap UpWhat's Next? - MarketBeat
uniQure (QURE) Stock Jumps in Pre-Market on Dec. 16, 2025: FDA AMT-130 Uncertainty, Analyst Price Targets, and Key Catalysts Ahead - ts2.tech
UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington's Data Spurs Mizuho Downgrade and Delayed Launch - Finviz
UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington’s Data Spurs Mizuho Downgrade and Delayed Launch - Insider Monkey
(QURE) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA - MSN
QURE INVESTIGATION: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):